Vivakor, Inc. quarterly report, Q2 FY2009

Vivakor, Inc. 10-Q Summary

Business Context and Reporting Period

This is a Quarterly Report (Form 10-Q) for Vivakor, Inc., a trans-disciplinary biomedical company focused on the discovery and development of medical devices and pharmaceuticals. The reporting period covers the three and six months ended June 30, 2009. The company is classified as a smaller reporting company and a shell company status is denied. As of July 31, 2009, there were 50,660,660 shares of common stock outstanding.

Key Financial Metrics

Metric Six Months Ended June 30, 2009 Six Months Ended June 30, 2008
Total Revenues $94,987 $145,000
Net Loss $(815,717) $(87,713)
Net Loss Attributable to Vivakor $(805,735) $(87,713)
Cash and Cash Equivalents (End of Period) $51,578 $2,096
Net Cash Used in Operating Activities $(86,091) $(13,892)
Total Current Liabilities $2,674,350 $2,410,617
Stockholders' Equity (Deficit) $(422,147) $293,570

Revenue Composition (6 Months 2009): Grant revenue ($74,700), Product sales ($20,287), and Research revenue ($0).
Major Expenses (6 Months 2009): Research and development ($582,571), General and administrative ($291,433), and Abandoned offering costs ($111,316).

Material Changes vs. Prior Period

  • Increased Losses: Net loss increased significantly from $87,713 in the prior year period to $815,717. This is primarily due to a $111,316 write-off of deferred offering costs and a substantial increase in R&D expenses ($582,571 vs. $87,675) driven by patent amortization from the HealthAmerica acquisition.
  • Revenue Shift: The company transitioned from research service revenue ($145,000 in 2008) to grant revenue ($74,700) and initial product sales ($20,287) in 2009. Research service revenue dropped to zero.
  • Liquidity Position: Cash on hand decreased from $145,669 at year-end 2008 to $51,578 at June 30, 2009, despite a cash balance increase compared to the prior year's interim period.
  • Debt and Liabilities: Current liabilities increased by approximately $263,000, driven by a rise in accrued wages and benefits (from $298,496 to $572,768) and loans from related parties.

Guidance, Outlook, Risks, and Unusual Items

  • Going Concern: Management explicitly states substantial doubt about the company's ability to continue as a going concern. The company lacks sufficient cash to fund operations for the next twelve months and relies on future financing, grants, or strategic arrangements.
  • Failed Capital Raise: A planned public offering (Form S-1) was terminated in April 2009 after failing to receive payment on subscriptions for 14.3 million shares. This resulted in the $111,316 write-off of offering costs.
  • Debt Default: The company is in default on a $1.4 million note payable related to the HealthAmerica acquisition, failing to make required monthly payments. The note holder (a shareholder entity) has not taken action to date.
  • Outlook: The company plans to seek additional capital through equity/debt offerings or partnerships. It expects R&D expenses to increase in 2009 as it expands development efforts.
  • Subsequent Events: On July 27, 2009, the Board authorized a new stock option plan and a new registration statement for a potential offering of 15 million shares at $0.23 per share.

Investor Verification Checklist

  • Cash Runway: Verify the company's ability to survive with only $51,578 in cash against current liabilities exceeding $2.6 million.
  • Debt Status: Confirm the status of the $1.4 million note payable default and whether the shareholder note holder has initiated any enforcement actions.
  • Financing Progress: Monitor the status of the new Form S-1 registration authorized in July 2009 and the likelihood of closing the proposed $3.45 million offering.
  • Revenue Sustainability: Assess the reliability of grant revenue (NIH award) and the scalability of initial product sales (VivaThermic vials, VivaBlend).
  • Related Party Transactions: Review the $380,660 in loans and advances from related parties and the terms of repayment.
Disclaimer:
This AI-generated summary by MetaQuotes is based on SEC filings and may contain errors. Verify important details against the original SEC filings.